BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12440223)

  • 1. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.
    Marshall JL; Rizvi N; Kauh J; Dahut W; Figuera M; Kang MH; Figg WD; Wainer I; Chaissang C; Li MZ; Hawkins MJ
    J Exp Ther Oncol; 2002; 2(6):325-32. PubMed ID: 12440223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
    Sandor V; Bakke S; Robey RW; Kang MH; Blagosklonny MV; Bender J; Brooks R; Piekarz RL; Tucker E; Figg WD; Chan KK; Goldspiel B; Fojo AT; Balcerzak SP; Bates SE
    Clin Cancer Res; 2002 Mar; 8(3):718-28. PubMed ID: 11895901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors.
    Shah MH; Binkley P; Chan K; Xiao J; Arbogast D; Collamore M; Farra Y; Young D; Grever M
    Clin Cancer Res; 2006 Jul; 12(13):3997-4003. PubMed ID: 16818698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates.
    Berg SL; Stone J; Xiao JJ; Chan KK; Nuchtern J; Dauser R; McGuffey L; Thompson P; Blaney SM
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):85-8. PubMed ID: 15042312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report.
    Piekarz RL; Robey R; Sandor V; Bakke S; Wilson WH; Dahmoush L; Kingma DM; Turner ML; Altemus R; Bates SE
    Blood; 2001 Nov; 98(9):2865-8. PubMed ID: 11675364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
    Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
    Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report.
    ; Fouladi M; Furman WL; Chin T; Freeman BB; Dudkin L; Stewart CF; Krailo MD; Speights R; Ingle AM; Houghton PJ; Wright J; Adamson PC; Blaney SM
    J Clin Oncol; 2006 Aug; 24(22):3678-85. PubMed ID: 16877737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of depsipeptide in refractory metastatic renal cell cancer.
    Stadler WM; Margolin K; Ferber S; McCulloch W; Thompson JA
    Clin Genitourin Cancer; 2006 Jun; 5(1):57-60. PubMed ID: 16859580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical and pharmacokinetic investigation of didemnin B, a cyclic depsipeptide.
    Dorr FA; Kuhn JG; Phillips J; von Hoff DD
    Eur J Cancer Clin Oncol; 1988 Nov; 24(11):1699-706. PubMed ID: 3208814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells.
    Kitazono M; Robey R; Zhan Z; Sarlis NJ; Skarulis MC; Aikou T; Bates S; Fojo T
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3430-5. PubMed ID: 11443220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
    Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
    Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
    Ryan QC; Headlee D; Acharya M; Sparreboom A; Trepel JB; Ye J; Figg WD; Hwang K; Chung EJ; Murgo A; Melillo G; Elsayed Y; Monga M; Kalnitskiy M; Zwiebel J; Sausville EA
    J Clin Oncol; 2005 Jun; 23(17):3912-22. PubMed ID: 15851766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II clinical trial of didemnin B in non-small-cell lung cancer: neuromuscular toxicity is dose-limiting.
    Shin DM; Holoye PY; Murphy WK; Forman A; Papasozomenos SC; Hong WK; Raber M
    Cancer Chemother Pharmacol; 1991; 29(2):145-9. PubMed ID: 1662119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
    Stevenson JP; Sun W; Gallagher M; Johnson R; Vaughn D; Schuchter L; Algazy K; Hahn S; Enas N; Ellis D; Thornton D; O'Dwyer PJ
    Clin Cancer Res; 2002 Aug; 8(8):2524-9. PubMed ID: 12171879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis.
    Kwon HJ; Kim MS; Kim MJ; Nakajima H; Kim KW
    Int J Cancer; 2002 Jan; 97(3):290-6. PubMed ID: 11774279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors.
    Eder JP; Ryan DP; Appleman L; Zhu AX; Puchalski T; He X; Sonnichsen DS; Cooper M; Wright J; Clark JW; Supko JG
    Cancer Chemother Pharmacol; 2006 Jul; 58(1):107-16. PubMed ID: 16362299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
    Schilsky RL; Hohneker J; Ratain MJ; Janisch L; Smetzer L; Lucas VS; Khor SP; Diasio R; Von Hoff DD; Burris HA
    J Clin Oncol; 1998 Apr; 16(4):1450-7. PubMed ID: 9552051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of didemnin B in advanced colorectal cancer.
    Jones DV; Ajani JA; Blackburn R; Daugherty K; Levin B; Patt YZ; Abbruzzese JL
    Invest New Drugs; 1992 Aug; 10(3):211-3. PubMed ID: 1428730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCR 20th Anniversary Commentary: Expanding the Epigenetic Therapeutic Portfolio.
    Bates SE; Robey RW; Piekarz RL
    Clin Cancer Res; 2015 May; 21(10):2195-7. PubMed ID: 25979924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical study of didemnin B. A National Cancer Institute of Canada Clinical Trials Group study.
    Maroun JA; Stewart D; Verma S; Eisenhauer E
    Invest New Drugs; 1998; 16(1):51-6. PubMed ID: 9740544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.